Alvotech (NASDAQ:ALVOW – Get Free Report) is expected to announce its results after the market closes on Wednesday, November 11th. Analysts expect Alvotech to post earnings of ($0.0197) per share and revenue of $134.22 million for the quarter.
Alvotech Stock Down 49.1%
Shares of NASDAQ:ALVOW opened at $0.15 on Wednesday. The business’s 50 day moving average is $0.35 and its 200 day moving average is $0.29. Alvotech has a 12-month low of $0.12 and a 12-month high of $1.14.
Alvotech Company Profile
Alvotech is a biotechnology company focused on developing and manufacturing biosimilar medicines. Biosimilars are biologic products designed to be highly similar to approved reference medicines and may provide additional treatment options in areas with significant healthcare costs. The company’s portfolio targets therapeutic categories including immunology, ophthalmology, oncology and other chronic conditions.
Alvotech operates an integrated business model that covers biosimilar research, cell-line development, process development, clinical testing and commercial-scale manufacturing.
Featured Articles
- Five stocks we like better than Alvotech
- Meta’s $100 Billion AI Financing Plan Has a Catch for Existing Shareholders
- Tower Semiconductor’s Earnings Are Soaring—So Why Is Its Stock Down More Than 50%?
- Shopify’s Small Q3 Miss Triggered a Big Sell-Off: What’s Next?
- Can Oil’s Big Rally Deliver Reliable Income? 3 Energy Plays to Watch
Receive News & Ratings for Alvotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alvotech and related companies with MarketBeat.com's FREE daily email newsletter.
